InsidersTradesSigma
申报总数
公司
▲ 买入（0 笔）
▼ 卖出（0 笔）
内部人交易记录
高级管理人员已披露买入
0
已披露卖出
0
尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
信号历史
无可用的信号评分。
Discover the detailed record of transactions filed by Hannah Alison l., Director. Director active across 4 companies, notably Neogenomics INC. Aggregated, 13 disclosures have been published. History available since 19 May 2021. The latest transaction was filed on 8 July 2026 (Attribution). Regulator: SEC (Form 4). All data is openly available.
Companies and markets linked to Hannah Alison l.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报13 总计
24,400 股0Common StockSEC:0000905148-26-003238:0
12,254 股0Common StockSEC:0001077183-25-000126:0
12,254 股0Common StockSEC:0001077183-25-000132:0
2,500 股0Common StockSEC:0000905148-25-001932:0
11,336 股0Common StockSEC:0001077183-24-000127:0
25,000 股0Common StockSEC:0000905148-24-001652:0
25,000 股0Common StockSEC:0001140361-23-034282:0
15,000 股0Common StockSEC:0001567619-22-014297:0
15,556 股0Common StockSEC:0001077183-22-000110:0
25,000 股0Common StockSEC:0001140361-22-020304:0
22,500 股0Common StockSEC:0001567619-22-002523:0
3,081 股0Common StockSEC:0001077183-21-000162:0
6,250 股0Common StockSEC:0001179110-21-005772:0
13 条申报中的 13 条
About Hannah Alison l.
Alison L. Hannah is a Board Member and Chief Medical Officer at NEOGENOMICS INC and RIGEL PHARMACEUTICALS INC. She oversees medical affairs and contributes to the company's strategy. Hannah plays a key role in innovation and the development of new treatments.
